GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioSpecifics Technologies Corp (NAS:BSTC) » Definitions » Net Margin %

BioSpecifics Technologies (BioSpecifics Technologies) Net Margin % : 47.86% (As of Sep. 2020)


View and export this data going back to 1991. Start your Free Trial

What is BioSpecifics Technologies Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. BioSpecifics Technologies's Net Income for the three months ended in Sep. 2020 was $5.39 Mil. BioSpecifics Technologies's Revenue for the three months ended in Sep. 2020 was $11.26 Mil. Therefore, BioSpecifics Technologies's net margin for the quarter that ended in Sep. 2020 was 47.86%.

The historical rank and industry rank for BioSpecifics Technologies's Net Margin % or its related term are showing as below:

BSTC' s Net Margin % Range Over the Past 10 Years
Min: -26.66   Med: 41.78   Max: 64.08
Current: 47.49


BSTC's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -155.475 vs BSTC: 47.49

BioSpecifics Technologies Net Margin % Historical Data

The historical data trend for BioSpecifics Technologies's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioSpecifics Technologies Net Margin % Chart

BioSpecifics Technologies Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.28 43.32 41.28 60.84 64.08

BioSpecifics Technologies Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.44 62.52 46.53 2.97 47.86

Competitive Comparison of BioSpecifics Technologies's Net Margin %

For the Biotechnology subindustry, BioSpecifics Technologies's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioSpecifics Technologies's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioSpecifics Technologies's Net Margin % distribution charts can be found below:

* The bar in red indicates where BioSpecifics Technologies's Net Margin % falls into.



BioSpecifics Technologies Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

BioSpecifics Technologies's Net Margin for the fiscal year that ended in Dec. 2019 is calculated as

Net Margin=Net Income (A: Dec. 2019 )/Revenue (A: Dec. 2019 )
=24.47/38.188
=64.08 %

BioSpecifics Technologies's Net Margin for the quarter that ended in Sep. 2020 is calculated as

Net Margin=Net Income (Q: Sep. 2020 )/Revenue (Q: Sep. 2020 )
=5.387/11.256
=47.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioSpecifics Technologies  (NAS:BSTC) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


BioSpecifics Technologies Net Margin % Related Terms

Thank you for viewing the detailed overview of BioSpecifics Technologies's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioSpecifics Technologies (BioSpecifics Technologies) Business Description

Traded in Other Exchanges
N/A
Address
35 Wilbur Street, Lynbrook, NY, USA, 11563
BioSpecifics Technologies Corp is a biopharmaceutical company that specializes in collagenase for multiple indications. Injectable collagenase is marketed in various geographic regions, including the U.S., the EU, and Australia, under the Xiaflex name. The targeted diseases are Dupuytren's contracture and Peyronie's disease. The company is also researching the development of Xiaflex as a solution for new potential indications, such as uterine fibroids, adhesive capsulitis, cellulite, lateral hip fat, plantar fibromatosis, and human and canine lipomas.
Executives
Paul Gitman director 167 EXECUTIVE DRIVE MANHASSET HILLS NY 11040
Michael Schamroth director 191 MEADOWVIEW AVENUE HEWLETT NY 11557
Toby Wegman director, 10 percent owner 4092 BOCAIRE BLVD. BOCA RATON FL 33487
Mark N Wegman director 43 OVERLOOK ROAD OSSINING NY 10562
Jennifer M Chao director 7 PURITAN WOODS ROAD, RYE NY 10580
Joseph Truitt director, officer: Chief Executive Officer C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Michael A. Sherman director 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Fishman Corey N. director DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Patrick Hutchison officer: Chief Financial Officer C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
J Kevin Buchi director, officer: Chief Executive Officer 41 MOORES ROAD, FRAZER PA 19355
Patrick M Caldwell officer: Principal Financial Officer C/O PROTINE DESIGN LAB 532 BELLA CALAIS WAY SAN JOSE CA 94138
Jyrki Mattila director AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Ronald Edward Law officer: SVP Business Development 23733 N. LOOKOUT PT. ROAD, LAKE BARRINGTON IL 60010
Thomas Wegman director, 10 percent owner, officer: President 1764 BRIAR PLACE MERRICK NY 11566
Estate Of Edwin H. Wegman 10 percent owner 4092 BOCAIRE BLVD. BOCA RATON FL 33487

BioSpecifics Technologies (BioSpecifics Technologies) Headlines